EU Agency backs new drugs from GSK, Novartis, J&J
LONDON Feb 21 (Reuters) - European regulators said on Friday they had recommended approval of 10 drugs, six of which were for respiratory diseases including GlaxoSmithKline's Anoro and Laventair and Novartis's Ulunar Breezhaler.
The European Medicine Agency (EMA) also gave the green light to Vokanamet, a treatment for type 2 diabetes marketed by Johnson & Johnson.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Canada's parliament attacked, soldier fatally shot nearby |
- NOAA employee charged with stealing U.S. dam information
- Sweden gets two new sightings, as hunt for undersea intruder goes on
- Canada probes Michael Zehaf-Bibeau as possible suspect in Ottawa shooting: source
- Special Report: Traffickers use abductions, prison ships to feed Asian slave trade